Document:

Exhibit 4.1

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE
SECURITIES.

 

 

	 	Right to Purchase _______________ shares of Common Stock of Aethlon Medical, Inc. (subject to adjustment as provided herein)

 

 

COMMON STOCK PURCHASE WARRANT

 

	No. _____________	Issue Date: ____________

 

AETHLON MEDICAL, INC.,
a corporation organized under the laws of the State of Nevada (the “Company”), hereby certifies that, for value received,
the_____________ (the “Holder”) is entitled, subject to the terms set forth below, to purchase from the Company at
any time commencing after the Issue Date until 5:00 p.m., P.S.T, on the Expiration Date (as defined below), up to _________ fully
paid and non-assessable shares of Common Stock at a per share purchase price of $0.132. The aforedescribed purchase price per
share, as adjusted from time to time as herein provided, is referred to herein as the "Purchase Price." This Common
Stock Purchase Warrant (this “Warrant”) is being issued to the Holder in connection with the conversion of that 10%
Convertible Promissory Note dated July__, 2013 issued by Company to Holder. This Warrant may be exercised at any time and from
time to time but no later than 5:00 p.m., P.S.T., seven years from the date of issuance of this Warrant (the “Expiration
Date”), at which point it shall become void and all rights under this Warrant shall cease.

 

As used herein the
following terms, unless the context otherwise requires, have the following respective meanings:

 

(a)The term “Company”
shall include Aethlon Medical, Inc. and any corporation which shall succeed or assume the obligations of Aethlon Medical, Inc.
hereunder.

 

(b)The term “Common
Stock” includes (a) the Company's Common Stock, $.001 par value per share, as authorized on the date of this Warrant,
and (b) any other securities into which or for which any of the securities described in (a) may be converted or exchanged
pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

 

    	1

    	 

    

(c)The term “Other
Securities” refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate
or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise
of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in
exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise.

 

(d)The term “Warrant
Shares” shall mean the Common Stock issuable upon exercise of this Warrant.

 

1.Exercise of
Warrant.

 

1.1.Number of
Shares Issuable upon Exercise. From and after the Issue Date through and including the Expiration Date, the Holder hereof shall
be entitled to receive, upon exercise of this Warrant in whole in accordance with the terms of subsection 1.2 or upon exercise
of this Warrant in part in accordance with subsection 1.3, shares of Common Stock of the Company, subject to adjustment pursuant
to Section 4.

 

1.2.Full Exercise.
This Warrant may be exercised in full by the Holder hereof by delivery of an original or facsimile copy of the form of subscription
attached as Exhibit A hereto (the “Subscription Form”) duly executed by such Holder and delivery within two (2)
days thereafter of payment, in cash, wire transfer or by certified or official bank check payable to the order of the Company,
in the amount obtained by multiplying the number of shares of Common Stock for which this Warrant is then exercisable by the Purchase
Price then in effect. The original Warrant is not required to be surrendered to the Company until it has been fully exercised.

 

1.3.Partial Exercise.
This Warrant may be exercised in part (but not for a fractional share) by delivery of a Subscription Form in the manner and at
the place provided in subsection 1.2, except that the amount payable by the Holder on such partial exercise shall be the amount
obtained by multiplying (a) the number of whole shares of Common Stock designated by the Holder in the Subscription Form by
(b) the Purchase Price then in effect. On any such partial exercise, provided the Holder has surrendered the original Warrant,
the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder hereof a new Warrant of like tenor,
in the name of the Holder hereof or as such Holder (upon payment by such Holder of any applicable transfer taxes) may request,
the whole number of shares of Common Stock for which such Warrant may still be exercised.

 

1.4.Company Acknowledgment.
The Company will, at the time of the exercise of the Warrant, upon the request of the Holder hereof, acknowledge in writing its
continuing obligation to afford to such Holder any rights to which such Holder shall continue to be entitled after such exercise
in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure shall not affect
the continuing obligation of the Company to afford to such Holder any such rights.

 

1.5Delivery
of Stock Certificates, etc. on Exercise. The Company agrees that the shares of Common Stock purchased upon exercise of this
Warrant shall be deemed to be issued to the Holder hereof as the record owner of such shares as of the close of business on the
date on which delivery of a Subscription Form shall have occurred and payment shall have been made for such shares as aforesaid.
As soon as practicable after the exercise of this Warrant in full or in part, and in any event within five (5) business days thereafter,
the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and
delivered to the Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in
compliance with applicable securities laws, a certificate or certificates for the number of duly and validly issued, fully paid
and non-assessable shares of Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise, plus,
in lieu of any fractional share to which such Holder would otherwise be entitled, cash equal to such fraction multiplied by the
then fair market value of one full share of Common Stock, together with any other stock or other securities and property (including
cash, where applicable) to which such Holder is entitled upon such exercise pursuant to Section 1 or otherwise. 

 

    	2

    	 

    

2.Adjustment
for Reorganization, Consolidation, Merger, etc.

 

2.1.Fundamental Transaction. 
If, at any time while this Warrant is outstanding, (A) the Company  effects any merger or  consolidation of
the Company with or into another entity, (B) the Company effects any sale of all or substantially all of its assets in
one or a series of related transactions,  (C) any tender offer or exchange offer (whether by
the Company or another entity) is completed pursuant to which holders of Common Stock are permitted to tender or exchange
their shares for other securities, cash or property, (D) the Company consummates a stock purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with one or more persons or entities whereby such other persons or entities acquire more than 50% of the outstanding shares of
Common Stock (not including any shares of Common Stock held by such other persons or entities making or party to, or associated
or affiliated with the other persons or entities making or party to, such stock purchase agreement or other business combination),
(E) any "person" or "group" (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act)
is or shall become the "beneficial owner" (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50%
of the aggregate Common Stock of the Company, or (F) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (in any such case, a "Fundamental  Transaction"), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that
would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at
the option of the Holder, (a) upon exercise of this Warrant, the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the "Alternate Consideration") receivable upon
or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets
by a Holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such
event or (b) if the Company is acquired in (1) a transaction where the consideration paid to the holders of
the Common Stock consists solely of cash, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the 1934 Act,
or (3) a transaction involving a person or entity not traded on a national securities exchange, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Nasdaq Capital Market, cash equal to the Black-Scholes Value.  For purposes of
any such exercise, the determination of the Purchase Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in
such Fundamental Transaction, and the Company shall apportion the Purchase Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. 
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
such Fundamental Transaction.  To the extent necessary to effectuate the foregoing provisions, any
successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with
the foregoing provisions and evidencing the Holder's right to exercise such warrant into Alternate
Consideration.  The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms
requiring any such successor or surviving entity to comply with the provisions of this Section 3.1 and insuring that
this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a
Fundamental Transaction. “Black-Scholes Value” shall be determined in accordance with the Black-Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg L.P. using (i) a price per share of Common Stock equal to the VWAP
of the Common Stock for the Trading Day immediately preceding the date of consummation of the applicable Fundamental Transaction,
(ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant
as of the date of such request and (iii) an expected volatility equal to the 100 day volatility obtained from the HVT function
on Bloomberg L.P. determined as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction.

 

    	3

    	 

    

2.2.Dissolution.
In the event of any sale or conveyance of all or substantially all of the assets of the Company in connection with a plan of complete
liquidation of the Company, or in the case of the dissolution, liquidation or winding-up of the Company, all rights under this
Warrant shall terminate on a date fixed by the Company, such date so fixed to be not earlier than the date of the commencement
of the proceedings for such dissolution, liquidation or winding-up and not later than thirty (30) days after such commencement
date. Notice of such termination of purchase rights shall be given to the Holder at least thirty (30) days prior to such termination
date.

 

2.3.Continuation
of Terms. Except as provided in Section 2.2, upon any reorganization, consolidation, merger or transfer referred to in this
Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the Other Securities
and property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation or merger,
as the case may be, and shall be binding upon the issuer of any Other Securities, including, in the case of any such transfer,
the person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have
expressly assumed the terms of this Warrant as provided in Section 3.1. In the event this Warrant does not continue in full
force and effect after the consummation of the transaction described in this Section 2, then the Company shall at its expense
deliver or cause to be delivered the securities and property (including cash, where applicable) receivable by the Holder of the
Warrants to a bank or trust company having its principal office in California, as trustee for the Holder of the Warrants. Such
property shall be delivered to the Holder only upon payment of the Warrant exercise price.

 

3.Extraordinary
Events Regarding Common Stock. In the event that the Company shall (a) issue additional shares of the Common Stock as
a dividend or other distribution on outstanding Common Stock, (b) subdivide its outstanding shares of Common Stock, or (c) combine
its outstanding shares of the Common Stock into a smaller number of shares of the Common Stock, then, in each such event, the Purchase
Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Purchase Price by a fraction,
the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator
of which shall be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall
thereafter be the Purchase Price then in effect. The Purchase Price, as so adjusted, shall be readjusted in the same manner upon
the happening of any successive event or events described herein in this Section 4. The number of shares of Common Stock that
the Holder of this Warrant shall thereafter, on the exercise hereof, be entitled to receive shall be adjusted to a number determined
by multiplying the number of shares of Common Stock that would otherwise (but for the provisions of this Section 4) be issuable
on such exercise by a fraction of which (a) the numerator is the Purchase Price that would otherwise (but for the provisions of
this Section 4) be in effect, and (b) the denominator is the Purchase Price in effect on the date of such exercise.

 

4.Certificate
as to Adjustments. In each case of any adjustment or readjustment in the shares of Common Stock (or Other Securities) issuable
on the exercise of the Warrants, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate
designee to compute such adjustment or readjustment in accordance with the terms of the Warrant and prepare a certificate setting
forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including
a statement of (a) the consideration received or receivable by the Company for any additional shares of Common Stock (or Other
Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or Other Securities)
outstanding or deemed to be outstanding, and (c) the Purchase Price and the number of shares of Common Stock to be received
upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as
provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder of the Warrant and any
Warrant Agent of the Company (appointed pursuant to Section 10 hereof).

 

    	4

    	 

    

5.Rights of
Holder. Nothing contained in this Warrant shall be construed as conferring upon the Holder the right to vote or consent or
receive notice as a stockholder in respect of any meetings of stockholders for the election of directors or any other matter, or
as having any rights whatsoever as a stockholder of the Company. If, however, at any time prior to the expiration of this Warrant
and prior to its exercise, any of the following shall occur:

 

5.1.The Company shall
take a record of the holders of its shares of Common Stock for the purpose of entitling them to receive a dividend or distribution
payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of current or retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company; or

 

5.2 There shall be
proposed any capital reorganization or reclassification of the Common Stock, or a sale of all or substantially all of the assets
of the Company, or a consolidation or merger of the Company with another entity;

 

then, in any one or more
of said cases, the Company shall cause to be mailed to the Holder, at the earliest practicable time (and, in any event, not less
than thirty (30) days before any record date or other date set for definitive action), written notice of the date on which the
books of the Company shall close or a record shall be taken to determine the stockholders entitled to such dividend or distribution
or entitled to vote on such reorganization, reclassification, sale, consolidation or merger, as the case may be. Such notice shall
also set forth such facts as shall indicate the effect of such action (to the extent such effect may be known at the date of such
notice) on the Purchase Price and the kind and amount of the Common Stock and other securities and property deliverable upon exercise
of this Warrant. Such notice shall also specify the date as of which the holders of the Common Stock of record shall participate
in said distribution or shall be entitled to exchange their Common Stock for securities or other property deliverable upon such
reorganization, reclassification, sale, consolidation or merger, as the case may be. Without limiting the obligation of the Company
to provide notice to the Holder of actions hereunder, it is agreed that failure of the Company to give notice shall not invalidate
such action of the Company.

 

6.Reservation
of Stock, etc. Issuable on Exercise of Warrant; Financial Statements. The Company will at all times reserve and keep available,
solely for issuance and delivery on the exercise of the Warrants, all shares of Common Stock (or Other Securities) from time to
time issuable on the exercise of the Warrant. This Warrant entitles the Holder hereof to receive copies of all financial and other
information distributed or required to be distributed to the holders of the Company's Common Stock.

 

7.Assignment;
Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby,
may be transferred by any registered holder hereof (a "Transferor"). On the surrender for exchange of this Warrant, with
the Transferor's endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form") and together
with an opinion of counsel reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance with
applicable securities laws, the Company will issue and deliver to or on the order of the Transferor thereof a new Warrant or Warrants
of like tenor, in the name of the Transferor and/or the transferee(s) (upon payment by such Holder of any applicable transfer taxes)
specified in such Transferor Endorsement Form (each a "Transferee"), calling in the aggregate on the face or faces thereof
for the number of shares of Common Stock called for on the face or faces of the Warrant so surrendered by the Transferor.

 

8.Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or
security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation
of this Warrant, the Company at its expense, twice only, will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

    	5

    	 

    

9.Registration
Under the Securities Act of 1933.

 

9.1.Registration
and Legends. The Holder understands that (i) the Company has not registered the Warrant or the Warrant Shares under the Securities
Act of 1933, as amended (the “Securities Act”), or the applicable securities laws of any state in reliance on exemptions
from registration and (ii) such exemptions depend upon the Holder's investment intent at the time the Holder acquires the Warrant
or the Warrant Shares. The Holder therefore represents and warrants that it is acquiring the Warrant, and will acquire the Warrant
Shares, for the Holder's own account for investment and not with a view to distribution, assignment, resale or other transfer of
the Warrant or the Warrant Shares. Because the Warrant and the Warrant Shares are not registered, the Holder is aware that the
Holder must hold them indefinitely unless they are registered under the Securities Act and any applicable securities laws or the
Holder must obtain exemptions from such registration. Upon exercise, in part or in whole, of this Warrant, the Warrant Shares shall
bear the following legend:

 

The shares of Common
Stock represented by this certificate have not been registered under the Securities Act of 1933, as amended ("Act") or
any applicable state securities laws, and they may not be offered for sale, sold, transferred, pledged or hypothecated without
an effective registration statement under the Act and under any applicable state securities laws, or an opinion of counsel, satisfactory
to the company, that an exemption from such registration is available.

 

 

 

10.Warrant Agent.
The Company may, by written notice to the Holder of the Warrant, appoint an agent (a “Warrant Agent”) for the purpose
of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 1, exchanging this Warrant
pursuant to Section 7, and replacing this Warrant pursuant to Section 8 or any of the foregoing, and thereafter any such
issuance, exchange or replacement, as the case may be, shall be made at such office by such Warrant Agent.

 

11.Transfer
on the Company's Books. Until this Warrant is transferred on the books of the Company, the Company may treat the registered
holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

 

12.Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: if to the Company, to: Aethlon Medical, Inc., 8910 University Center Lane, Suite 660, San Diego,
CA 92122, Attn: James A. Joyce, CEO, telecopier: (858) 272-2738,and (ii) if to the Holder, to the Holder’s last known address
and telecopier number as it shall appear on the books of the Company.

 

    	6

    	 

    

13.Law Governing
This Warrant. This Warrant shall be governed by and construed in accordance with the laws of the State of California without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Warrant shall be brought only in the state courts of California or in the federal courts located in the state and county
of California. The parties to this Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The
Company and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's
fees and costs. In the event that any provision of this Warrant or any other agreement delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Warrant by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any other manner permitted by law.

 

14.Survival.
All agreements, covenants, representations and warranties herein shall survive the execution and delivery of this Warrant and any
investigation at any time made by or on behalf of any parties hereto and the exercise, sale and purchase of this Warrant (and any
other securities or property) issuable on exercise hereof.

 

15.Binding Effect.
All the covenants and provisions of this Warrant by or for the benefit of the Company shall bind and inure to the benefit of its
successors and assigns hereunder.

 

16.Parties Bound
and Benefitted. Nothing in this Warrant expressed and nothing that may be implied from any of the provisions hereof is intended,
or shall be construed, to confer upon, or give to, any person or corporation other than the Company and the Holder any right, remedy
or claim under promise or agreement hereof, and all covenants, conditions, stipulations, promises and agreements contained in this
Warrant shall be for the sole and exclusive benefit of the Company and its successors and of the Holder, its successors and, if
permitted, its assignees.

 

IN WITNESS WHEREOF,
the Company has executed this Warrant as of the date first written above.

 

	 	AETHLON MEDICAL, INC.

                            

                            

                           By:     /s/ James Frakes

                           Name: James Frakes

                           Chief Financial Officer      

 

  

    	7

    	 

    

 

 

 

	 	HOLDER:
	 	 
	 	 
	 	 
	 	By:
	 	Name:
	 	Title:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	8

    	 

    

 

 

Exhibit A

 

FORM OF SUBSCRIPTION

(to be signed only on exercise of Warrant)

 

TO: AETHLON MEDICAL, INC.

 

The undersigned, pursuant to the provisions
set forth in the attached Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

 

___          ________
shares of the Common Stock covered by such Warrant.

 

The undersigned herewith makes payment of the
full purchase price for such shares at the price per share provided for in such Warrant, which is $___________. Such payment takes
the form of $__________ in lawful money of the United States.

 

The undersigned requests that the certificates
for such shares be issued in the name of, and delivered to ________________________ whose address
is

 

 

 

 

 

 

The undersigned represents and warrants that
all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to
registration of the Common Stock under the Securities Act of 1933, as amended (the "Securities Act"), or pursuant to
an exemption from registration under the Securities Act.

 

	Dated:___________________	 
	 	(Signature must conform to name of holder as specified on the face of the Warrant)
	 	 
	 	 
	 	 
	 	(Address)

 

 

 

 

 

 

 

 

 

 

 

    	9

    	 

    

 

 

 

Exhibit B

 

 

FORM OF TRANSFEROR ENDORSEMENT

(To be signed only on transfer of Warrant)

For value received, the
undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading "Transferees" the right
represented by the within Warrant to purchase the percentage and number of shares of Common Stock of AETHLON MEDICAL, INC. to which
the within Warrant relates specified under the headings "Percentage Transferred" and "Number Transferred,"
respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on
the books of AETHLON MEDICAL, INC. with full power of substitution in the premises.

 

	Transferees	Percentage Transferred	Number Transferred
	 	 	 
	 	 	 
	 	 	 

 

 

	
        Dated: ______________, ___________
	 	
         

	Signed in the presence of	 	
        (Signature must conform to name of holder as specified
on the face of the warrant)

	 	 	 
	 	 	 
	(Name)	 	 
	 	 	
        (address)

	 	 	 
	
        

        

         
	 	 
	ACCEPTED AND AGREED:	 	 
	[TRANSFEREE]	 	 
	 	 	(address)
	 	 	 
	(Name)	 	

 

 

 

 

 

 

 

 

 

 

 

    	10Exhibit 10.37

 

 

AMENDMENT TO AGREEMENT
FOR THE SUBSCRIPTION OF SHARES

 

This Amendment to Agreement
for the Subscription of Shares (this “Amendment”) is dated July 24, 2014, and amends the Agreement for the Subscription
of Shares (the “Agreement for Subscription”), dated as of May 20, 2014, between SurePure, Inc., a Nevada corporation
(the “Corporation”), and Trinity Asset Management (Proprietary) Limited, a company formed under the laws of South Africa
(Company Number: 1996/010864/07) (the “Manager”). Capitalized terms used in this Amendment without definition
shall have the respective meanings given them in the Agreement for Subscription.

 

WHEREAS, the Company
and the Manager have entered into the Agreement for Subscription, under which the Manager agreed to provide Offers to Purchase
for the Offered Shares;

 

WHEREAS, in the Agreement
for Subscription the Manager agreed that it would perform its obligations by July 30, 2014;

 

WHEREAS, as of the
date of this Amendment, the Manager has not provided any Offers to Purchase but has in good faith requested that the Corporation
extend the Termination Date to September 30, 2014 to provide the Manager with additional time to perform its obligations under
the Agreement for Subscription; and

 

WHEREAS, the board
of directors of the Corporation has determined that it would be in the best interests of the Corporation and its shareholders for
the Manager to be granted additional time in which to perform its obligations under the Agreement for Subscription.

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Corporation and the Manager agree as follows:

 

1.             The definition of Termination Date in Section 1.1 of the Agreement for Subscription is hereby amended to be September 30, 2014.

 

 

2.             The definition of Transfer Agent in Section 1.1 of the Agreement for Subscription is hereby amended to read in full as follows:

 

“Transfer Agent” means Vstock
Transfer, LLC, the current transfer agent of the Corporation, with a mailing address of 18 Lafayette Place, Woodmere, NY 11598,
United States of America, and any successor transfer agent of the Corporation.

 

3.             The Agreement for Subscription shall remain unmodified and unamended in all other respects.

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to Agreement for the Subscription of Shares to be duly executed by their respective
authorized signatories as of the date first indicated above.

 

	 	SUREPURE, INC.
	 	 
	 	By: 	/s/Stephen M. Robinson
	 	 	Name: Stephen M. Robinson
Title: Chief Financial Officer

 

	 	TRINITY ASSET MANAGEMENT (PROPRIETARY)
        LIMITED
	 	 
	 	By: 	/s/Quinton George
	 	 	Name: Quinton George
Title: Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]